Clinical Performance of a Liquid Preservation Medium for Cervicovaginal Samples in DNA ‐ HPV Testing and Liquid‐Based Cytology for Cervical Cancer Screening
Cytopathology · 2025
DOI: 10.1111/cyt.13495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytopathology, 2025. Verfasst von Larissa Dias Assunção und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Papillomaviridae, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erviegas Group.
Abstract (Originalsprache)
Introduction
Cervical cancer remains a significant global health concern, primarily associated with persistent infections by high‐risk human papillomavirus (hr‐HPV). As screening programmes evolve from traditional cytology to DNA‐HPV testing, the need for a liquid medium that maintains the integrity of cervical samples for biomolecular analysis and cytology becomes critical.
Methods
This study evaluated the performance of the candidate liquid preservation medium (PM) Cytoliq for cervical samples intended for DNA‐HPV testing and liquid‐based cytology (LBC), in comparison with the reference PM, PreservCyt‐ThinPrep. A total of 112 women aged 18–64 years underwent routine gynaecological examinations, with paired cervical samples preserved in both PM for HPV testing and genotyping (Cobas HPV test), and LBC. The study aimed for a sensitivity greater than 90% in detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+), moderate to high agreement in HPV testing results (Kappa index > 0.70) and adequate performance in LBC.
Results
The candidate PM exhibited non‐inferior performance relative to the reference PM. DNA‐HPV testing showed a 94.5% agreement rate (Kappa = 0.88) and a sensitivity of 92.9% for CIN2+ detection. Additionally, the candidate PM performed well in LBC smear production, with no significant differences in cytological diagnoses. The agreement in LBC diagnoses was 94.0% (Kappa = 0.79) with the ThinPrep processor and 91.8% (Kappa = 0.63) with the Cytoliq processor.
Conclusion
The Cytoliq PM demonstrated comparable efficacy to the reference for DNA‐HPV testing and LBC, supporting its potential as an alternative preservation medium in cervical cancer screening programmes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
- Department of Pathology, Federal University of Sao Paulo, Sao Paulo, Brazil.
ORCID-Profile: Julio Cesar Teixeira
Förderung
- Erviegas Group
Zitieren
APA
Assunção, L. D., Discacciati, M. G., da Silva, A. G., Yoshida, A., Vale, D. B., & Teixeira, J. C. (2025). Clinical Performance of a Liquid Preservation Medium for Cervicovaginal Samples in DNA ‐ HPV Testing and Liquid‐Based Cytology for Cervical Cancer Screening. Cytopathology. https://doi.org/10.1111/cyt.13495
Vancouver
Assunção LD, Discacciati MG, da Silva AG, Yoshida A, Vale DB, Teixeira JC. Clinical Performance of a Liquid Preservation Medium for Cervicovaginal Samples in DNA ‐ HPV Testing and Liquid‐Based Cytology for Cervical Cancer Screening. Cytopathology. 2025. doi:10.1111/cyt.13495
BibTeX
@article{Assuno2025,
author = {Assunção, Larissa Dias and Discacciati, Michelle Garcia and da Silva, Andressa Germano and Yoshida, Adriana and Vale, Diama Bhadra and Teixeira, Julio Cesar},
title = {Clinical Performance of a Liquid Preservation Medium for Cervicovaginal Samples in DNA ‐ HPV Testing and Liquid‐Based Cytology for Cervical Cancer Screening},
journal = {Cytopathology},
year = {2025},
doi = {10.1111/cyt.13495}
}
EUVIMED